INTRODUCTION AND OBJECTIVES:
To investigate the detailed mechanism of erectile dysfunction (ED) induced by hyperhomocysteinaemia (HHcy) in rats and determine whether the Human Tissue Kallikrein 1 (hKLK1) might improve it, as we have proved the protective role of hKLK1 on erectile function in aged rats.
METHODS: We established a rat model of HHCy through dietary-rich methionine (Met) in male Sprague-Dawley (SD) rats. Male wild-type SD rats (WTR) and transgenic rats harboring the hKLK1 gene (TGR) were fed to 10 weeks of age. Then 24 WTRs were divided into control (n¼8), the low-dose (4% Met, n¼8), and the highdose (7% Met, n¼8). Another 8 age-matched TGRs with the highdose formed the TGR+7%Met group. 30 days later, erectile function, level of total homocysteinaemia (tHcy), oxidative stress, endothelial function, cavernous nerve function and fibrosis of all groups were determined.
RESULTS: hKLK1 in the TGR+7%Met group could greatly decrease the tHcy levels and improve ED induced by HHcy in rats. For the endothelial function, hKLK1 could preserve the endothelial cell-cell junction, enhance endothelial regeneration and activated the Akt/eNOS signaling pathway. Together with the promotion of hKLK1 on nNOS expression, the NO/cGMP signaling pathway activity was also increased. For the fibrosis, hKLK1 could preserve normal corpus cavernosum structure through inhibiting apoptosis and promoting autophagy on corpus cavernosum smooth muscle cells. In addition, hKLK1 also inhibited the fibrosis-related signaling pathway activity.
CONCLUSIONS: hKLK1 might effectively improve ED induced by HHcy in rats by protecting endothelial function, promoting cavernous nerve function and inhibiting fibrosis, which suggested hKLK1 might be a potential treatment method for ED.
Source of Funding: none

MP43-19 A CONTEMPORARY ASSESSMENT OF NORMAL ERECTION PHYSIOLOGY
Katherine Cockerill*, Jacksonville, FL; Ram Pathak, Winston-Salem, NC; Ciarra Boyne, Gregory Broderick, Jacksonville, FL INTRODUCTION AND OBJECTIVES: Classic studies using invasive caversonometry have associated a rigid erection with sustained intracavernous pressures > 80-90 mm Hg with erection pressures reaching supra-diastolic pressures during activation of bulbocavernous muscle contraction associated with pelvic stimulation. The contemporary assessment of erectile complaints relies on noninvasive color duplex Doppler ultrasound imaging (CDDU). The CDDU parameters associated with rigid erection are End Diastolic Flow Velocity ¼ 0 (EDV0) or EDV reversed (EDVr), when intracavernous pressures equals or exceeds the diastolic blood pressure, respectively. The aim of our study is to identify age-specific diastolic blood pressure (DBP) parameters for patients who achieved normal rigidity following penile injection of Alprostadil associated with EDV0 or EDVr during CDDU.
METHODS: We retrospectively reviewed 97 men complaining of erectile dysfunction (ED) who demonstrated normal/sustained rigidity. Blood pressure measurements were recorded at the time of CDDU. Other parameters recorded were Peak Systolic Velocity, Resistive Index, EDV, age, BMI, co-morbidities and duration of erectile dysfunction complaints.
RESULTS: A total of 97 patients with a median age of 57 years and a mean BMI of 26.6 underwent CDDU. All patients achieved rigid erection following PGE1 injection; all but three patients required alphaadrenergic injection for erection reversal at 60 minutes. Fourteen patients were classified as EDV0 (18.5%) and 83 patients were classified as EDVr (85.5%). Twenty-nine patients (29.9%) had a diagnosis of hypertension. The mean DBP at time of CDDU was 76.7 mm Hg (with SD ¼ 10.7). The mean diastolic blood pressure between men with EDV0 and EDVr was not significantly different (79.7 vs. 75.8 mm Hg, p ¼ 0.13). For patients age <50 years with EDV0, the median DBP was 79 with interquartile range (71, 83). For patients age > 50 years with EDV0, the median DBP was 85 with IQR (73, 89). For patients age < 50 years with EDVr, the median DBP was 76 with IQR (70, 81). For patients age > 50 years with EDVr, the median DBP was 78 with IQR (66, 84).
CONCLUSIONS: Our study suggests that the previously established parameters for intracavernous pressure >80-90 mm Hg for normal erection may be too high. We found mean diastolic blood pressures of 75-79 mmHg in men complaining of ED who had vascular normal erections following intracavernous Alprostadil.
Source of Funding: None
MP43-20
INTRODUCTION AND OBJECTIVES: Considering ED in patients with diabetes had seriously affected the quality of life. However, these patients showed a poor effect rate for the first-line oral phosphodiesterase type 5 (PDE5) inhibitors. Thus, new treatment methods are urgently needed. To investigate whether JTE-013 supplementation could improve diabetes mellitus-induced erectile dysfunction (DMED).
METHODS: We used 50 male Sprague-Dawley (SD) rats (8-week-old) for the experiment. Of these, 42 were induced Type?DM through the streptozotocin (STZ), and other 8 normal rats constituted the Control group. 8 weeks later, we assessed the erectile function of rats through an apomorphine test. Only rats with DMED were treated with JTE-013 intraperitoneal injection each day for 4 weeks, and other rats were bred in the same condition for 4 weeks.
RESULTS: At 12 weeks after diabetes was induced, fasting glucose concentrations were significantly higher in the DMED group than the other two groups. JTE-013 supplementation could partially reduce the level of fasting glucose. Erectile function in the DMED group was significantly impaired compared with the Control group, and was partially, but significantly, improved in the DMED + JTE-013 group. The DMED group showed the highest level of S1PR2/RhoA/ ROCK/p-MYPT1 signaling pathway activation among all groups, and the DMED + JTE-013 group showed more activation than the Control group. The DMED group showed serious corporal fibrosis, higher level of apoptosis index and expressions of the TGF-b1/ROCK/LIMK2/ Cofilin pathway. However, JTE-013 supplementation partially inhibited corporal fibrosis and the apoptosis level, and reduced the activation of these pathways.
CONCLUSIONS: JTE-013 supplementation inhibited endothelial dysfunction and corporal fibrosis, leading ultimately to partial improvement of DMED in rats. Our finding provided evidences for a potential treatment method for DMED.
